Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07006792 · ClinicalTrials.gov registry record · Phase 4
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
A Phase 4 study of Atopic Dermatitis, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT07006792 is a Phase 4 study of Atopic Dermatitis that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 200 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT07006792, a Phase 4 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
Conditions Studied
Interventions
- DRUG Lebrikizumab
Study Locations (20)
Florida
- Suncoast Research Associates - Doral
- Encore Medical Research - Hollywood
- Solutions Through Advanced Research - Jacksonville
- Life Arc Research Centers - Miami - Miami
- MCR Research - Miami
- Health Clinical Research - Miami
- Deluxe Health Center - Miami Lakes
- Renstar Medical Research - Ocala
- Leading Edge Dermatology - Plantation
- Research Institute of the Southeast - West Palm Beach
California
- California Dermatology & Clinical Research Institute - Encinitas
- First OC Dermatology Research Inc - Fountain Valley
- Dermatology Research Associates - Los Angeles
- NorCal Clinical Research - Rocklin
Arizona
- Research Solutions of Arizona - Litchfield Park
- Alliance Dermatology and Mohs Center - Phoenix
Alabama
- Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology - Birmingham
Georgia
- Dermatology Affiliates Research Institute - Atlanta
Illinois
- DeNova Research - Chicago
Indiana
- Southern Indiana Clinical Research Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07006792
The ClinicalTrials.gov registry entry for NCT07006792 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Lebrikizumab is the first listed.
NCT07006792 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07006792 about?
NCT07006792 is a clinical study titled "A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden". The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 ...
What is the current status of trial NCT07006792?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2025-06-16. Estimated completion is 2026-09.
What conditions does trial NCT07006792 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT07006792?
The interventions under investigation include: Lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT07006792?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07006792 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
Molecular Signatures of Cutaneous Dupilumab Response
RECRUITING · Phase 4
-
Ethnic Differences in Mechanisms of Action of Dupilumab
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 4
-
Dupilumab De-escalation in Pediatric Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.